Buy Rating Affirmed: G1 Therapeutics' Cosela Shows Significant Survival Benefits in MTNBC
Needham Reiterates Buy on G1 Therapeutics, Maintains $12 Price Target
G1 Therapeutics Analyst Ratings
Buy Rating Affirmed for G1 Therapeutics Amid Promising Clinical Outcomes
Analysts Offer Insights on Healthcare Companies: Personalis (PSNL) and G1 Therapeutics (GTHX)
Strategic Licensing Agreements and Revenue Forecast Uphold Buy Rating for G1 Therapeutics
G1 Therapeutics Analyst Ratings
G1 Therapeutics Analyst Ratings
Optimistic Buy Rating for G1 Therapeutics Amidst Solid Financial Footing and Cosela's Market Expansion
G1 Therapeutics: A Buy Rating on Promising Trials and Robust Financial Outlook
G1 Therapeutics Analyst Ratings
Buy Rating for G1 Therapeutics: Market Position and Growth Potential Solidify Investment Appeal
G1 Therapeutics Analyst Ratings
Analysts Offer Insights on Healthcare Companies: Immunocore Holdings (IMCR), Palatin Technologies (PTN) and G1 Therapeutics (GTHX)
Analysts Are Bullish on These Healthcare Stocks: G1 Therapeutics (GTHX), Kiniksa Pharmaceuticals (KNSA)
G1 Therapeutics Analyst Ratings
Analysts' Opinions Are Mixed on These Healthcare Stocks: CymaBay Therapeutics (CBAY), G1 Therapeutics (GTHX) and Gritstone Oncology (GRTS)
Buy Rating on G1 Therapeutics Highlighting Cosela's Clinical Progress and Strong Market Potential
Analysts Offer Insights on Healthcare Companies: Medtronic (MDT), Centessa Pharmaceuticals (CNTA) and G1 Therapeutics (GTHX)
Analysts Offer Insights on Healthcare Companies: G1 Therapeutics (GTHX) and Apellis Pharmaceuticals (APLS)
No Data